Defining metastatic renal-cell carcinoma as a favorable risk depends on clinical risk-stratification tools such as the International Metastatic Renal Cell Carcinoma Database Consortium or the Memorial Sloan-Kettering Cancer Center scores. The favorable-risk disease tends to have better prognosis and survival compared with disease stratified as either intermediate or poor risk and can be attributed in part to an indolent tumor biology. Several phase 3 clinical trials have demonstrated an improvement in progression-free survival and objective response rate, but not overall survival benefit with combinations of immunotherapy and vascular endothelial growth factor tyrosine kinase inhibitors compared with sunitinib in favorable-risk disease.
Hematology/oncology clinics of North America. 2023 May 29 [Epub ahead of print]
Elizabeth Pan, Danielle Urman, Carmel Malvar, Rana R McKay
University of California San Diego, Moores Cancer Center, 3855 Health Sciences Drive, #0987, La Jolla, CA 92093-0987, USA., University of California San Diego, Moores Cancer Center, 3855 Health Sciences Drive, #0987, La Jolla, CA 92093-0987, USA. Electronic address: .